胃癌肝转移的综合治疗进展

doi:10.3760/cma.j.cn371439-20200629-00079

摘要/Abstract

摘要：

胃癌是临床上最常见的消化系统恶性肿瘤之一,具有异质性强、进展快和预后差等特点。胃癌肝转移是造成晚期胃癌死亡最主要的原因。目前,临床上胃癌的治疗方式主要包括系统治疗(全身化疗、靶向治疗、免疫治疗)、手术切除、介入治疗及放疗等,但治疗效果均欠佳,胃癌肝转移更是缺乏规范化的治疗策略。目前,多学科综合治疗模式在恶性肿瘤诊疗中广泛应用,取得了很好的效果。中国胃肠外科专家组根据胃癌肝转移的临床特点及手术可及性,将其分为3大临床类型,分别为可切除型、潜在可切除型及不可切除型。各种临床类型的患者需多学科综合治疗协作组专家讨论后制定出个体化的治疗方案。

关键词: 胃肿瘤, 肝转移, 临床分型, 多学科综合治疗

Abstract:

Gastric cancer is one of the most common malignant tumors of digestive system, which has the characteristics of strong heterogeneity, rapid progress and poor prognosis. Liver metastasis of gastric cancer is the main cause of death of advanced gastric cancer. At present, the clinical treatment of gastric cancer mainly includes systematic treatment (systemic chemotherapy, targeted treatment, immunotherapy), surgical resection, interventional treatment and radiotherapy, but the therapeutic effects are not good, and liver metastasis of gastric cancer is lack of standardized treatment strategy. At present, the multi-disciplinary comprehensive treatment mode has been widely used in the diagnosis and treatment of malignant tumors, and has achieved good results. According to the clinical characteristics and surgical accessibility of liver metastasis of gastric cancer, the Chinese Gastrointestinal Surgery Expert Group divides it into three clinical types: resectable type, potential resectable type and non-resectable type. All kinds of clinical types of patients need multidisciplinary comprehensive treatment cooperation group experts to discuss and formulate individualized treatment plan.

Key words: Stomach neoplasms, Liver metastasis, Clinical classification, Multi-disciplinary comprehensive therapy

宋美娇, 沈庆林, 张锡泉, 姚伟荣. 胃癌肝转移的综合治疗进展[J]. 国际肿瘤学杂志, 2020, 47(9): 565-568.

Song Meijiao, Shen Qinglin, Zhang Xiquan, Yao Weirong. Advance in comprehensive treatment of liver metastasis of gastric cancer[J]. Journal of International Oncology, 2020, 47(9): 565-568.

参考文献 27

[1]	Zhang Y, Lin Y, Duan J, et al. A population-based analysis of distant metastasis in stage Ⅳ gastric cancer[J]. Med Sci Monit, 2020,26:e923867. DOI: 10.12659/MSM.923867. doi: 10.12659/MSM.923867 pmid: 32409630
[2]	Tang K, Zhang B, Dong L, et al. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer[J]. J Int Med Res, 2020,48(7):300060520940509. DOI: 10.1177/0300060520940509. doi: 10.1177/0300060520940509 pmid: 32687001
[3]	廖孝枫, 刘合利, 刘鹏. 可切除的局部进展期胃癌及转移性胃癌治疗现状及进展[J]. 中南大学学报(医学版), 2020,45(4):426-434. DOI: 10.11817/j.issn.1672-7347.2020.190079.
[4]	中国研究型医院学会消化道肿瘤专业委员会, 中国医师协会外科医师分会上消化道外科医师委员会, 中国抗癌协会胃癌专业委员会, 等. 胃癌肝转移诊断与综合治疗中国专家共识(2019版)[J]. 中国实用外科杂志, 2019,39(5):405-411. DOI: 10.19538/j.cjps.issn1005-2208.2019.05.01.
[5]	Cui JK, Liu M, Shang XK. Hepatectomy for liver metastasis of gastric cancer: a meta-analysis[J]. Surg Innov, 2019,26(6):692-697. DOI: 10.1177/1553350619856491. doi: 10.1177/1553350619856491 pmid: 31267829
[6]	Montagnani F, Crivelli F, Aprile G, et al. Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors[J]. Cancer Treat Rev, 2018,69:11-20. DOI: 10.1016/j.ctrv.2018.05.010. doi: 10.1016/j.ctrv.2018.05.010
[7]	Solaini L, Ministrini S, Bencivenga M, et al. Conversion gastrectomy for stage Ⅳ unresectable gastric cancer: a GIRCG retrospective cohort study[J]. Gastric Cancer, 2019,22(6):1285-1293. DOI: 10.1007/s10120-019-00968-2. doi: 10.1007/s10120-019-00968-2 pmid: 31065878
[8]	Kawahara K, Makino H, Kametaka H, et al. Outcomes of surgical resection for gastric cancer liver metastases: a retrospective analysis[J]. World J Surg Oncol, 2020,18(1):41. DOI: 10.1186/s12957-020-01816-9. doi: 10.1186/s12957-020-01816-9 pmid: 32093729
[9]	Guner A, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines[J]. Transl Gastroenterol Hepatol, 2019,4:58. DOI: 10.21037/tgh.2019.08.03. doi: 10.21037/tgh
[10]	Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials[J]. Int J Surg, 2018,51:120-127. DOI: 10.1016/j.ijsu.2018.01.008. doi: 10.1016/j.ijsu.2018.01.008 pmid: 29413875
[11]	Liu Y, Zhao G, Xu Y, et al. Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer[J]. Int J Radiat Oncol Biol Phys, 2017,98(5):1096-1105. DOI: 10.1016/j.ijrobp.2017.03.032. doi: 10.1016/j.ijrobp.2017.03.032 pmid: 28721893
[12]	Ilson DH. Advances in the treatment of gastric cancer[J]. Curr Opin Gastroenterol, 2018,34(6):465-468. DOI: 10.1097/MOG.0000000000000475. doi: 10.1097/MOG.0000000000000475
[13]	Song JC, Ding XL, Zhang Y, et al. Prospective and prognostic factors for hepatic metastasis of gastric carcinoma: a retrospective analysis[J]. J Cancer Res Ther, 2019,15(2):298-304. DOI: 10.4103/jcrt.JCRT_576_17. doi: 10.4103/jcrt.JCRT_576_17 pmid: 30964101
[14]	Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol, 2017,39(7):10104283177-14626. DOI: 10.1177/1010428317714626.
[15]	Ilhan-Mutlu A, Taghizadeh H, Beer A, et al. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis[J]. Cancer Biol Ther, 2018,19(3):169-174. DOI: 10.1080/15384047.2017.1414759. doi: 10.1080/15384047.2017.1414759 pmid: 29252101
[16]	Wang K, Zhang X, Wei J, et al. Hepatic arterial infusion oxaliplatin plus oral S-1 chemotherapy in gastric cancer with unresectable liver metastases: a case series and literature review[J]. Cancer Manag Res, 2020,12:863-870. DOI: 10.2147/CMAR.S233123. doi: 10.2147/CMAR.S233123 pmid: 32104068
[17]	Ceniceros L, Chopitea A, Pardo F, et al. Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience[J]. Clin Transl Oncol, 2018,20(5):658-665. DOI: 10.1007/s12094-017-1767-2. doi: 10.1007/s12094-017-1767-2 pmid: 29043568
[18]	Ge S, Xia X, Ding C, et al. A proteomic landscape of diffuse-type gastric cancer[J]. Nat Commun, 2018,9(1):1012. DOI: 10.1038/s41467-018-03121-2. doi: 10.1038/s41467-018-03121-2
[19]	Lane WO, Nussbaum DP, Sun Z, et al. Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: should lymph node retrieval guidelines be altered[J]. J Surg Oncol, 2018,117(8):1708-1715. DOI: 10.1002/jso.25068. doi: 10.1002/jso.25068 pmid: 29799615
[20]	Guner A, Son T, Cho I, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation[J]. Gastric Cancer, 2016,19(3):951-960. DOI: 10.1007/s10120-015-0522-z. doi: 10.1007/s10120-015-0522-z pmid: 26231353
[21]	杨希夷. 高强度聚焦超声联合动脉灌注化疗治疗胃癌术后肝转移的临床疗效评估[J]. 国际肿瘤学杂志, 2015,42(12):950-951. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.018. doi: 10.3760/cma.j.issn.1673-422X.2015.12.018
[22]	Liang F. The KEYNOTE-061 trial[J]. Lancet, 2019,393(10176):1098. DOI: 10.1016/S0140-6736(18)33073-3. doi: 10.1016/S0140-6736(18)33073-3 pmid: 30894265
[23]	Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. doi: 10.1016/S0140-6736(17)31827-5 pmid: 28993052
[24]	Gong W, Su Y, Liu A, et al. Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma[J]. Neoplasma, 2018,65(3):326-330. DOI: 10.4149/neo_2018_170207N84. doi: 10.4149/neo_2018_170207N84 pmid: 29788728
[25]	Izuishi K, Mori H. Recent strategies for treating stage Ⅳ gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiothe-rapy[J]. J Gastrointestin Liver Dis, 2016,25(1):87-94. DOI: 10.15403/jgld.2014.1121.251.rv2. doi: 10.15403/jgld.2014.1121.251.rv2 pmid: 27014758
[26]	Omori H, Tanizawa Y, Makuuchi R, et al. Role of palliative resection in patients with incurable advanced gastric cancer who are unfit for chemotherapy[J]. World J Surg, 2019,43(2):571-579. DOI: 10.1007/s00268-018-4816-2. doi: 10.1007/s00268-018-4816-2 pmid: 30298282
[27]	Tokunaga M, Makuuchi R, Miki Y, et al. Surgical and survival outcome following truly palliative gastrectomy in patients with incurable gastric cancer[J]. World J Surg, 2016,40(5):1172-1177. DOI: 10.1007/s00268-015-3398-5. doi: 10.1007/s00268-015-3398-5 pmid: 26754075